Clinical Trials Logo

Retinal Perforations clinical trials

View clinical trials related to Retinal Perforations.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT06200727 Active, not recruiting - Glaucoma Clinical Trials

Platelet-rich Fibrin(PRF) Membrane in Ophthalmic Diseases

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to observe the role of PRF in treating ophthalmic diseases.The efficacy and safety of PRF were validated for four ophthalmic conditions: macular hole, pterygium, corneal ulcer, and patients undergoing trabeculectomy for glaucoma. The main question aims to answer is PRF's effectiveness in ocular surface and fundus diseases. Participants will be divided into 2 groups, the experimental group will be treated with PRF and the control group will be treated with conventional surgery, with a 12-month postoperative follow-up to determine the role of PRF on wound healing in ophthalmic diseases.

NCT ID: NCT06194760 Active, not recruiting - Retinal Detachment Clinical Trials

Evaluation of Vitrectomy With ILM Peeling in Myopic Macular Hole With Only Posterior Retinal Detachment

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

Retinal detachment (RD) resulting from the macular hole (MH), also known as MH-induced RD (MHRD), most commonly occurs in eyes with high myopia and results in irreversible visual disorders. Although ILM peeling for MHRD reportedly achieves a high retinal reattachment rate that ranges from 70% to 100%, the MH closure rate is relatively low, ranging from 10% to 70%.

NCT ID: NCT05875909 Active, not recruiting - Clinical trials for Myopia, Degenerative

Corneal Flap Transplantation for Macular Hole Repair of High Myopia

Start date: February 23, 2022
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to learn about an innovative surgical technique for macular hole repair. This technique is for patients with high myopia using pars plana vitrectomy (PPV) combined with corneal flap transplantation. The main questions it aims to answer are: - Is the innovative surgical technique useful for patients? - Is the surgical technique safe for patients? Participants will: - Undergo PPV combined with corneal flap transplantation to cover the macular hole. - Maintain a prone position for 2 weeks postoperatively. - Be observed by visual acuity, slit lamp, optical coherence tomography (OCT) and fundus photography for 1 year after surgery.

NCT ID: NCT04904679 Active, not recruiting - Macular Holes Clinical Trials

The Use of Amniotic Membrane or Internal Limiting Membrane for Large or Refractory Macular Holes: A Prospective Study

Start date: June 26, 2020
Phase: N/A
Study type: Interventional

Prospective, randomized, unmasked interventional study. To evaluate anatomical and functional results through microperimetry in cases of refractory or large macular holes (MH), using amniotic membrane (AM) or internal limiting membrane ( ILM ).

NCT ID: NCT03528122 Active, not recruiting - Retinal Detachment Clinical Trials

Amniotic Membrane for Recurrent Macular Hole

Start date: February 1, 2018
Phase: N/A
Study type: Interventional

Macular hole surgery were tried by different surgeons using many techniques with different successes but still there were many recurrences. In this study the investigators try to close these distinct types including recurrent holes using pre-prepared amniotic membrane.

NCT ID: NCT03465865 Active, not recruiting - Macular Hole Clinical Trials

Visual Acuity and Optical Coherence Tomography One Year After ILM-flap Transposition

Start date: September 1, 2017
Phase:
Study type: Observational

ILM-flap (internal limiting Membrane-flap) transposition is a new surgical option in repair of macular holes, therefore one year outcomes are needed to better evaluate that method.

NCT ID: NCT03437759 Active, not recruiting - Macular Holes Clinical Trials

MSC-Exos Promote Healing of MHs

MSCs
Start date: March 1, 2017
Phase: Early Phase 1
Study type: Interventional

Purpose: To assess the safety and efficacy of mesenchymal stem cells (MSCs) and MSC-derived exosomes (MSC-Exos) for promoting healing of large and refractory macular holes (MHs). Hypothesis: MSC and MSC-Exo therapy may promote functional and anatomic recovery from MH. MSC-Exo therapy may be a useful and safe method for improving visual outcomes of surgery for refractory MHs.